Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
It's an investigational drug currently in Phase 3 clinical trials Eli Lilly's TRIUMPH Phase 3 program includes multiple trials for obesity, type 2 diabetes, NASH, and cardiovascular outcomes Expected timeline: FDA submission in 2026, potential approval in 20272028 Phase 2 results showed 24.2% weight loss at 48 weeks, the highest ever recorded for a GLP-1 class medication How to access now: Clinical trial enrollment (free), compounding pharmacies (with important legal caveats), or research peptides (grey market) When approved, retatrutide will be the first triple-agonist obesity medication (GLP-1 + GIP + glucagon) Is Retatrutide FDA Approved
For clinical trial participants and healthcare professionals: always follow the storage instructions on the IMP label and those provided by the trial site pharmacist
Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: Insights from meta-analysis of randomised controlled trials and real-world evidence
For GLP-1 receptor agonists, microdosing means using doses significantly below the standard therapeutic range, typically one-fifth to one-tenth of what is prescribed for weight loss or diabetes management
If a video visit is required, it will typically be for the initial session
According to the company, refund processing may take up to 14 business days after the returned package is received and inspected
US$ 24.60
US$ 29.14
US$ 21.43
US$ 25.51
US$ 26.78
